NDASEC stock news
This page provides real-time market news, earnings updates, and company announcements related to NDA Securities Ltd. (NDASEC).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-24 15:08 IST
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
Finviz2026-03-19 13:49:11
EchoStar's $42.6 Billion Spectrum Move: A Rapid Expansion Investment or Pay-TV Merger Threat
101 finance2026-03-19 14:21:53
Biofrontera (BFRI) Q4 2025 Financial Results Transcript
101 finance2026-03-19 15:24:57
Enanta’s pediatric RSV findings lower risk and pave the way for a pivotal adult Phase 3 milestone
101 finance2026-03-19 16:51:58
CervoMed's Biomarker-Driven Subgroup Response Strengthens Phase 3 Case but Raises Near-Term Funding Urgency
101 finance2026-03-19 21:21:50
Relmada Therapeutics Inc.'s 2025 Q4 Call: 12-Month Data Timing, Phase 3 Enrollment, and R&D Cost Signals Don’t Match
101 finance2026-03-19 22:43:39
Eton Pharma (ETON) Quarterly Earnings Conference Call Transcript
101 finance2026-03-19 22:57:10
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call
101 finance2026-03-19 23:06:47
Corcept's Insiders Are Selling Millions—Is the FDA Warning Just the Beginning?
101 finance2026-03-20 09:06:47
Minerva’s $293M Burn Sets Up High-Stakes Phase 3 Binary Bet
101 finance2026-03-20 12:33:59
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026
101 finance2026-03-20 16:39:56
Verrica Encounters Legal Trigger—Could This Be an Undervalued Opportunity for a Short Squeeze?
101 finance2026-03-21 00:12:43
Corcept's July 11 PDUFA Could Overshadow April Lawsuit Deadline as Ovarian Cancer Data Revives Pipeline
101 finance2026-03-21 05:37:16
Dizal’s ZEGFROVY Nears First-Line Standard Status as Phase 3 Win Unlocks New Market
101 finance2026-03-21 12:03:40
Rhythm Pharma’s FDA Approval for HO Expansion Sparks Valuation Opportunity During Biotech Market Volatility
101 finance2026-03-22 03:03:46
Alumis (ALMS) Faces Binary Setup: Upcoming SLE Data Could Break the TYK2 "Pipeline-in-a-Pill" Thesis
101 finance2026-03-22 06:33:56
Travere (TVTX) Hinges on April 13 FDA Decision—FSGS Approval Could Unlock Wide Moat or Trigger Sharp De-Rating
101 finance2026-03-22 06:36:51
Alumis Shares Drop After Phase 3 Victory—Market Factors in Achievements, Ongoing Dilution, and Elevated Cash Burn as Main Concerns
101 finance2026-03-22 06:54:47
AQST CEO Sells 15% Stake While Buying Options—Smart Money Waits for Lawsuit and Resubmission Clarity
101 finance2026-03-22 22:40:06
Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA).
老虎证券2026-03-23 11:26:55
Gyre's Hydronidone Approaches 2026 NDA Filing—Will Production Ramp Up to Satisfy China's Rapidly Growing Fibrosis Demand?
101 finance2026-03-23 13:09:45
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-23 20:09:49
Serina Therapeutics (SER) Offers High-Risk, High-Reward Setup as Financing Ties Fate to Trial Dosing in Q3 2026
101 finance2026-03-23 20:55:03
Corcept Insiders Divided Over Shares: Director Invests $3.3M While CEO Receives Options and Outlook Stays Bearish
101 finance2026-03-23 21:15:38
CervoMed's Biomarker-Driven Subgroup Response Strengthens Phase 3 Case but Raises Near-Term Funding Urgency
101 finance2026-03-19 21:21:50
Relmada Therapeutics Inc.'s 2025 Q4 Call: 12-Month Data Timing, Phase 3 Enrollment, and R&D Cost Signals Don’t Match
101 finance2026-03-19 22:43:39
Eton Pharma (ETON) Quarterly Earnings Conference Call Transcript
101 finance2026-03-19 22:57:10
Curis Inc’s NHL Prioritization, PCNSL Timeline Shifts, and CLL Data Delays Clash in 2025 Q4 Earnings Call
101 finance2026-03-19 23:06:47
Corcept's Insiders Are Selling Millions—Is the FDA Warning Just the Beginning?
101 finance2026-03-20 09:06:47
Minerva’s $293M Burn Sets Up High-Stakes Phase 3 Binary Bet
101 finance2026-03-20 12:33:59
Biotech share surges 372% before being sold as latest selection climbs 40% in 2026
101 finance2026-03-20 16:39:56
Verrica Encounters Legal Trigger—Could This Be an Undervalued Opportunity for a Short Squeeze?
101 finance2026-03-21 00:12:43
Corcept's July 11 PDUFA Could Overshadow April Lawsuit Deadline as Ovarian Cancer Data Revives Pipeline
101 finance2026-03-21 05:37:16
Dizal’s ZEGFROVY Nears First-Line Standard Status as Phase 3 Win Unlocks New Market
101 finance2026-03-21 12:03:40
Rhythm Pharma’s FDA Approval for HO Expansion Sparks Valuation Opportunity During Biotech Market Volatility
101 finance2026-03-22 03:03:46
Alumis (ALMS) Faces Binary Setup: Upcoming SLE Data Could Break the TYK2 "Pipeline-in-a-Pill" Thesis
101 finance2026-03-22 06:33:56
Travere (TVTX) Hinges on April 13 FDA Decision—FSGS Approval Could Unlock Wide Moat or Trigger Sharp De-Rating
101 finance2026-03-22 06:36:51
Alumis Shares Drop After Phase 3 Victory—Market Factors in Achievements, Ongoing Dilution, and Elevated Cash Burn as Main Concerns
101 finance2026-03-22 06:54:47
AQST CEO Sells 15% Stake While Buying Options—Smart Money Waits for Lawsuit and Resubmission Clarity
101 finance2026-03-22 22:40:06
Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA).
老虎证券2026-03-23 11:26:55
Gyre's Hydronidone Approaches 2026 NDA Filing—Will Production Ramp Up to Satisfy China's Rapidly Growing Fibrosis Demand?
101 finance2026-03-23 13:09:45
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-23 20:09:49
Serina Therapeutics (SER) Offers High-Risk, High-Reward Setup as Financing Ties Fate to Trial Dosing in Q3 2026
101 finance2026-03-23 20:55:03
Corcept Insiders Divided Over Shares: Director Invests $3.3M While CEO Receives Options and Outlook Stays Bearish
101 finance2026-03-23 21:15:38
NDASEC stock price change
On the last trading day, NDASEC stock closed at 36.68 INR, with a price change of -4.73% for the day.
Trade stock perpsNDASEC stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more